Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $633
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $612 to $633.
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $612 to $633.